Executive Summary / Key Takeaways
- Waldencast's dual-brand beauty platform thesis is under severe operational strain, with supply chain disruptions, an ongoing SEC investigation, and material internal control weaknesses creating a gap between management's guidance and execution reality.
- The August 2025 strategic review, while potentially unlocking value through a sale or breakup, signals that the standalone multi-brand strategy may have failed, making this a binary event-driven situation rather than a traditional growth investment.
- A high 14.75% interest rate on new debt, rising quarterly, creates urgent cash flow pressure that limits strategic flexibility and forces difficult trade-offs between growth investment and financial survival.
- Despite these headwinds, both Obagi Medical and Milk Makeup maintain strong competitive positions in their respective categories, with Obagi ranking as the fastest-growing brand among the top 10 professional skincare players and Milk Makeup achieving success with new launches.
- The investment case hinges on whether management can deliver mid-teens revenue growth and mid-to-high-teens EBITDA margins in 2025 while simultaneously addressing legal, operational, and balance sheet risks—a combination that appears increasingly tenuous given Q1 2025 performance and deteriorating segment margins.
Setting the Scene: A SPAC Platform in Search of Stability
Waldencast plc, incorporated in December 2020 as a Cayman Islands blank check company and completed its IPO in March 2021, represents a post-SPAC beauty platform experiment. The July 2022 transformation—acquiring Obagi Global Holdings and Milk Makeup for $1.2 billion—was meant to create a repeatable "Waldencast Flywheel Effect" where the company would acquire, accelerate, and scale conscious, high-growth beauty brands. Nearly three years later, that flywheel has wobbled.
The company operates in two distinct beauty segments that are each riding industry tailwinds. Obagi Medical occupies the professional skincare channel, selling physician-dispensed products targeting aging, hyperpigmentation, and skin texture. This market is growing at 8% annually, outpacing prestige skincare's 2% growth, as consumers increasingly seek clinically-proven solutions over cosmetic marketing claims. Milk Makeup competes in the clean makeup category, where vegan, cruelty-free formulations have captured Gen-Z and Gen-Alpha consumers, growing faster than the overall U.S. market.
Waldencast's strategic positioning is theoretically sound: Obagi provides high-margin, recurring revenue from medical professionals who prescribe regimens, while Milk offers faster growth and brand heat through social media moments. The problem is execution. Supply chain disruptions have created persistent out-of-stock situations for both brands, an SEC investigation stemming from accounting restatements has consumed management attention and legal fees, and a $152 million goodwill impairment in 2025 suggests the acquisitions may have been overpriced. These issues culminated in August 2025 when the board announced a strategic review of alternatives to maximize shareholder value, effectively putting the company "in play."
Business Model and Strategic Differentiation: Two Paths, One Platform
Waldencast's business model relies on different channel strategies for its two brands, creating both diversification and complexity. Obagi Medical sells through physician-dispensed, direct-to-consumer e-commerce, and international distributors in over 95 countries. This professional channel commands premium pricing and generates high gross margins—76.2% in 2025—because dermatologists and medical spas recommend products as part of treatment protocols, creating built-in customer loyalty. Milk Makeup distributes primarily through U.S. and international retail partners like Sephora (MC) and Ulta Beauty (ULTA), plus its own e-commerce site, targeting the 64.7% gross margin range typical for color cosmetics.
The strategic differentiation lies in clinical credibility. Obagi is the number one physician-recommended medical-grade skincare brand for pigmentation, fine lines, and sagging skin, with products like the Nu-Derm system backed by decades of clinical data. This matters because it creates a moat that mass-market competitors cannot easily replicate. When a dermatologist prescribes a 4% hydroquinone regimen for melasma, patients don't price-shop at Ulta. Milk Makeup's differentiation is its clean positioning and product innovation, exemplified by the Cooling Water Jelly Tint becoming a major beauty launch in the U.S. in 2024.
However, the platform thesis is showing cracks. The "Waldencast Flywheel Effect"—where operational efficiencies fund marketing reinvestment—has been disrupted by supply chain costs and one-time expenses. The 2025 adjusted EBITDA margin declined to 5.9% for the consolidated business, down from 11.2% in 2023, as supply chain transformation costs, inventory write-offs, and legal expenses consumed profits. The strategic review suggests management may no longer believe the standalone platform story, making this a potential breakup or sale situation rather than a pure execution play.
Financial Performance: Numbers That Tell a Story of Strain
Waldencast's 2025 financial results reveal a company simultaneously growing and contracting. Consolidated net revenue declined 0.7% to $272.1 million, yet this masks divergent segment performance. Obagi Medical grew revenue 8.2% to $161.6 million, while Milk Makeup contracted 11.4% to $110.4 million. Milk's decline stemmed from international markets (-$19.8 million) due to retailer inventory destocking and soft consumption, while U.S. retail and DTC channels grew double-digits. This suggests the brand's underlying health remains intact, but distribution timing is creating volatility.
Margin deterioration is a concerning signal. Obagi's adjusted EBITDA margin compressed from 20.4% in 2024 to 12% in 2025, an 840 basis point decline that management attributes to increased marketing investment and higher supply chain costs. Milk Makeup's margin declined from 23.3% to 13.7%. These reflect structural cost increases from supply chain transformation and the expense of launching into new retailers like Ulta Beauty. The implication is that the brands may have been under-invested in infrastructure pre-acquisition, and Waldencast is now paying for catch-up spending.
The balance sheet shows financial engineering under pressure. Cash increased from $16.3 million to $31.9 million, but only after the company refinanced into a $225 million Lumina term loan carrying a 14.75% initial interest rate that rises 0.25% quarterly. This is high-cost financing, with early prepayment penalties that lock Waldencast into these terms. Net debt reached $172.1 million by Q1 2025, creating a high debt-to-EBITDA ratio given the $16.1 million adjusted EBITDA. The 14.75% rate means over $25 million in annual interest expense, consuming potential free cash flow and leaving minimal room for error.
The $152 million goodwill impairment is a significant financial signal. Split between $132 million for Obagi and $20 million for Milk, this non-cash charge indicates that projected synergies and growth assumptions from the 2022 acquisitions have not materialized as expected. Management notes both reporting units now have a narrow margin between their carrying values and fair values, meaning further impairments are possible if performance doesn't improve. This validates concerns that the platform value creation thesis is under pressure.
Segment Deep Dive: Obagi Medical's Supply Chain Squeeze
Obagi Medical's 8.2% revenue growth to $161.6 million in 2025 masks underlying demand that is stronger. Management states that growth was tempered by out-of-stock issues in key SKUs, and that the brand was the fastest-growing among the top 10 professional skincare brands in the U.S. in 2024. This demonstrates that the brand's market position is strengthening even as operational challenges limit sales capture. The physician channel shows robust demand, and new product launches like the ELASTIderm Lift Up & Sculpt franchise grew 189%.
The supply chain transformation initiative—consolidating third-party logistics providers and optimizing distribution centers—created disruptions. In Q1 2025, out-of-stock situations persisted, and adjusted EBITDA margin fell to 16.3% from 20.4% in the prior year period. Management aims to improve reactivity given the increasing levels of demand, but the timing is difficult. The company is losing sales today to build capacity for tomorrow, a trade-off that requires execution to improve in the coming quarters.
The July 2025 acquisition of Novaestiq Corp. for Saypha dermal filler rights represents a strategic pivot into aesthetic solutions, directly competing with Allergan's (ABBV) Juvederm and Galderma's (GALD) Restylane. FDA approval for Obagi Saypha MagIQ in September 2025 and the ALOHA partnership with VIO Med Spa to generate real-world evidence show progress. However, this expansion requires capital and management attention while supply chain issues affect the core business.
Segment Deep Dive: Milk Makeup's Viral-to-Volume Challenge
Milk Makeup's 11.4% revenue decline in 2025 is primarily an international phenomenon, suggesting a timing and distribution issue rather than a brand health crisis. U.S. retail sales grew high single-digits in Q1 2025, driven by the Ulta Beauty launch in 600 doors and the success of Hydro Grip Gel Skin Tint. The brand ranks number 14 in U.S. earned media value with 83% growth, indicating consumer desirability.
The Ulta Beauty launch is strategically critical. Ulta reaches a different demographic than Sephora, and management is focusing on distribution expansion to maintain productivity per store. The initial performance validates the decision, but launch setup costs compressed Q1 gross margin by 180 basis points to 69.5%. This is a common trade-off of retail expansion: investing in fixtures, marketing, and inventory to secure shelf space, with the expectation that velocity justifies the cost. For Milk, the goal is for Ulta to drive significant incremental annual revenue, though the margin profile may remain pressured through 2025.
International expansion shows promise but remains volatile. Launches in the UK (Boots), Scandinavia (Lyko), Germany (Douglas) (DOU), and India (Sephora) are performing well, yet international revenue declined in 2025 due to retailer inventory adjustments. This highlights the risk of distributor-based models where the company lacks direct control over ordering patterns, creating volatility that obscures underlying sell-through trends. The company is shifting to direct operations in Southeast Asia for Obagi, suggesting a similar path may be needed for Milk.
Competitive Context: Niche Strength vs. Scale Disadvantage
Waldencast's competitive positioning is a study in contrasts. Against pure-play professional skincare competitor The Beauty Health Company (SKIN), Waldencast demonstrates revenue stability—flat growth versus a 10% decline for its peer—though both face supply chain issues. The peer's device-based HydraFacial model generates recurring consumables revenue with 65.3% gross margins, but its capital equipment sales are cyclical. Waldencast's topical regimen model offers predictable repurchase patterns, but its 76.2% gross margins are currently offset by higher SG&A, resulting in a 12% EBITDA margin.
Compared to Estée Lauder (EL) and L'Oréal (OR), Waldencast's scale disadvantage is significant. Estée Lauder's $14.3 billion in skincare revenue and L'Oréal's dermatological beauty division dwarf Waldencast's $272 million, giving the larger companies superior purchasing power and R&D scale. However, Waldencast's professional exclusivity creates a moat that mass-market prestige brands cannot easily cross. When Obagi launches a 4% hydroquinone prescription product, it competes in a regulated channel that mass-market brands cannot access without repositioning. This provides pricing power and customer loyalty that partially offset scale disadvantages.
Bausch Health (BHC) offers a parallel with its dermatology segment, yet Waldencast's focused skincare approach contrasts with a broader pharma-derm portfolio. Bausch Health's $10.3 billion revenue base and 25.8% operating margin reflect pharma-scale efficiencies, but its high debt burden creates financial stress. Waldencast's smaller size allows faster innovation cycles—new Obagi products can launch in 12-18 months versus longer pharma timelines—but limits bargaining power with suppliers, contributing to supply chain fragility.
The key competitive vulnerability is Waldencast's limited scale in an industry where marketing spend drives awareness. Milk Makeup's 83% EMV growth is notable, but e.l.f. Beauty (ELF) can deploy massive marketing campaigns. Waldencast's SG&A budget must cover two brands, international expansion, and legal defense, creating a resource allocation challenge that larger competitors do not face.
Risks and Asymmetries: Where the Thesis Breaks
The SEC investigation represents a significant factor for the investment thesis. Initiated after Waldencast self-reported accounting review issues and received a subpoena in September 2023, the investigation has cost $10.6 million in legal fees and contributed to material weaknesses in internal controls that remain unremediated as of December 31, 2025. The risk includes potential difficulty meeting Sarbanes-Oxley auditor attestation requirements by fiscal 2026, which could impact listing status or covenants. The ongoing nature of the investigation creates an overhang that affects valuation and management focus.
Supply chain vulnerabilities are an immediate operational risk. Management's focus on improving the flexibility of the supply chain follows a period where cost efficiency objectives were prioritized over resilience. The out-of-stock issues have affected key SKUs for both brands, potentially ceding market share to competitors like SkinCeuticals and e.l.f. Beauty while impacting retailer relationships. If the transformation does not yield normalized fulfillment soon, full-year guidance may be difficult to achieve.
The Lumina Credit Agreement's 14.75% interest rate, rising 0.25% quarterly with payment-in-kind features, creates financial pressure. At current EBITDA levels, the company pays over $25 million annually in interest. Prepayment penalties and make-whole premiums effectively lock Waldencast into these terms until 2028. This increases the importance of the strategic review, as the company may need to sell assets or refinance within 18 months.
Goodwill impairment risk remains. With both reporting units carrying values just above fair value, macroeconomic volatility or missed revenue targets could trigger additional impairments. The $152 million charge in 2025 reduced the equity cushion; a second impairment could impact debt covenants. This creates a binary outcome: successful execution could lead to a rerate on improved asset values, while further challenges could lead to forced asset sales.
Valuation Context: Distressed Pricing for a Reason
At $0.90 per share, Waldencast trades at an enterprise value of $233.9 million, or 0.86 times trailing revenue of $272.1 million. This multiple sits below the 2.13x average for Estée Lauder and 1.7x for L'Oréal, but above the 0.38x for The Beauty Health Company. The valuation reflects the market's assessment of the company's operational and financial risks relative to its brand assets.
The balance sheet provides limited support. With $31.9 million in cash but $172.1 million in net debt, Waldencast has a limited liquidity buffer before needing to draw additional credit. The current ratio of 1.70 and quick ratio of 0.80 suggest near-term liquidity, but the 14.75% interest rate on the Lumina facility means every quarter of delay adds incremental interest expense.
Traditional valuation metrics are challenged by negative profitability. Management's guidance for mid-to-high-teens EBITDA margins in 2025 implies $40-50 million in adjusted EBITDA, which would value the company at 4.7-5.8x EV/EBITDA. However, Q1 2025 EBITDA performance puts the full-year target at risk.
The strategic review creates a potential valuation floor. Comparable transactions in beauty have commanded 1.5-2.5x revenue for strong brands, suggesting Obagi alone could be valued significantly based on its $161.6 million revenue. Milk Makeup could also attract interest given its clean positioning and momentum. Combined, the parts may exceed the current market valuation, making a breakup a possible outcome of the strategic review.
Conclusion: A Platform at the Precipice
Waldencast's investment thesis has shifted from a growth story about building a multi-brand beauty platform to a situation hinging on strategic alternative execution. The underlying brands retain competitive strength—Obagi's physician leadership and Milk's appeal are not easily replicated—but operational challenges, legal overhang, and high-cost financing have impacted the platform's ability to capture that value.
The strategic review announced in August 2025 is both an opportunity and a pivot. A sale to a strategic buyer like L'Oréal or Unilever (UL) could unlock upside as acquirers pay for synergies and brand equity. Conversely, a failed process or forced asset sale under pressure could see the stock trade lower.
For investors, the critical variables are whether management can stabilize supply chains to hit growth guidance and whether the strategic review concludes with a credible buyer before debt service impacts remaining equity value. The 14.75% interest rate creates a ticking clock, while the SEC investigation and internal control weaknesses limit options. This is a race against time where execution determines whether shareholders capture brand value or debt holders take control of the assets.
